IL130762A - Quinoline and quinazoline compounds, pharmaceutical compositions comprising them, process for their preparation and use thereof in the manufacture of medicaments for the treatment of benign prostatic hyperplasia - Google Patents
Quinoline and quinazoline compounds, pharmaceutical compositions comprising them, process for their preparation and use thereof in the manufacture of medicaments for the treatment of benign prostatic hyperplasiaInfo
- Publication number
- IL130762A IL130762A IL13076298A IL13076298A IL130762A IL 130762 A IL130762 A IL 130762A IL 13076298 A IL13076298 A IL 13076298A IL 13076298 A IL13076298 A IL 13076298A IL 130762 A IL130762 A IL 130762A
- Authority
- IL
- Israel
- Prior art keywords
- medicaments
- quinoline
- manufacture
- preparation
- treatment
- Prior art date
Links
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 title 2
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 title 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 125000002294 quinazolinyl group Chemical class N1=C(N=CC2=CC=CC=C12)* 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9700504.5A GB9700504D0 (en) | 1997-01-11 | 1997-01-11 | Pharmaceutical compounds |
| PCT/EP1998/000143 WO1998030560A1 (en) | 1997-01-11 | 1998-01-06 | Quinoline and quinazoline compounds useful in therapy, particularly in the treatment of begnin prostatic hyperplasia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL130762A0 IL130762A0 (en) | 2001-01-28 |
| IL130762A true IL130762A (en) | 2005-12-18 |
Family
ID=10805838
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL13076298A IL130762A (en) | 1997-01-11 | 1998-01-06 | Quinoline and quinazoline compounds, pharmaceutical compositions comprising them, process for their preparation and use thereof in the manufacture of medicaments for the treatment of benign prostatic hyperplasia |
Country Status (45)
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9700504D0 (en) | 1997-01-11 | 1997-02-26 | Pfizer Ltd | Pharmaceutical compounds |
| GB9708917D0 (en) * | 1997-05-01 | 1997-06-25 | Pfizer Ltd | Compounds useful in therapy |
| IL141235A (en) * | 2000-02-09 | 2012-04-30 | Novartis Int Pharm Ltd | Combined use of an alpha-adrenoceptor antagonist and a muscarinic antagonist in the preparation of a drug for the treatment of non-malignant prostatic hyperplasia |
| HUP0300006A3 (en) * | 2000-03-03 | 2006-01-30 | Pfizer | 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline mesylat and polymorphs, process for their preparation and pharmaceutical compositions containing them |
| KR100602929B1 (ko) | 2000-08-31 | 2006-07-20 | 에프. 호프만-라 로슈 아게 | 알파-1 아드레날린성 길항제로서 퀴나졸린 유도체 |
| US6900220B2 (en) | 2001-01-02 | 2005-05-31 | Syntex (U.S.A.) Llc | Quinazolone derivatives as alpha 1A/B adrenergic receptor antagonists |
| DE60110844T2 (de) * | 2001-01-02 | 2006-01-12 | F. Hoffmann-La Roche Ag | Chinazolone derivate als alfa 1a/b adrenozeptor antagonisten |
| US6734303B2 (en) | 2001-05-18 | 2004-05-11 | Pfizer Inc. | Process for the production of quinazolines |
| GB0112061D0 (en) * | 2001-05-18 | 2001-07-11 | Pfizer Ltd | Process for the production of quinazolines |
| GB0118752D0 (en) * | 2001-08-01 | 2001-09-26 | Pfizer Ltd | Process for the production of quinazolines |
| US7163696B2 (en) | 2001-10-11 | 2007-01-16 | Pfizer Inc. | Pharmaceutical formulations |
| GB0124455D0 (en) * | 2001-10-11 | 2001-12-05 | Pfizer Ltd | Pharmaceutical formulations |
| GB0206033D0 (en) * | 2002-03-14 | 2002-04-24 | Pfizer Ltd | Compounds useful in therapy |
| EP2277867B1 (en) * | 2002-07-15 | 2012-12-05 | Symphony Evolution, Inc. | Compounds, pharmaceutical compositions thereof and their use in treating cancer |
| GB0219961D0 (en) | 2002-08-28 | 2002-10-02 | Pfizer Ltd | Oxytocin inhibitors |
| GB0221582D0 (en) * | 2002-09-17 | 2002-10-23 | Pfizer Ltd | Method of treatment |
| GB0221579D0 (en) * | 2002-09-17 | 2002-10-23 | Pfizer Ltd | Combinations of atorvastatin and, adrenergic receptor antagonists |
| AU2003263455A1 (en) | 2002-09-26 | 2004-04-19 | Pfizer Inc. | Pyrazole amides for treating hiv infections |
| GB0225908D0 (en) * | 2002-11-06 | 2002-12-11 | Pfizer Ltd | Treatment of female sexual dysfunction |
| DK1572173T3 (da) | 2002-12-13 | 2010-06-14 | Warner Lambert Co | Alpha-2-delta-ligand til behandling af symptomer i den nedre urinvej |
| ATE366242T1 (de) * | 2003-07-02 | 2007-07-15 | Hoffmann La Roche | 5-substituierte chinazolinonderivate |
| US7291640B2 (en) | 2003-09-22 | 2007-11-06 | Pfizer Inc. | Substituted triazole derivatives as oxytocin antagonists |
| ATE520403T1 (de) * | 2003-09-26 | 2011-09-15 | Exelixis Inc | N-ä3-fluoro-4-(ä6-(methyloxy)-7-ä(3-morpholin-4 ylpropyl)oxyüquinolin-4-ylüoxy)phenylü-n'-(4- fluorophenyl)cyclopropane-1,1-dicarboxamid zur behandlung von krebs |
| WO2005089804A2 (en) * | 2004-03-16 | 2005-09-29 | Pfizer Limited | Combinations of hmg-coa reductase inhibitors and alpha1 adrenergic receptor antagonists |
| KR20050092519A (ko) * | 2004-03-16 | 2005-09-22 | 화이자 인코포레이티드 | 아토르바스타틴 및 α1-아드레날린성 수용체 길항제의 조합 |
| BRPI0510453A (pt) | 2004-04-30 | 2007-10-30 | Warner Lambert Co | composto substituìdos com morfolina para o tratamento de distúrbios do sistema nervoso central |
| WO2008084493A2 (en) * | 2007-01-09 | 2008-07-17 | Unichem Laboratories Limited | A novel process for the preparation of 2-halo-4-aminoquinazolines |
| JP2009126784A (ja) * | 2007-11-19 | 2009-06-11 | Mitsubishi Gas Chem Co Inc | ２−ヨード−３，４−ジメトキシベンゾニトリルの製造方法。 |
| JP2009126785A (ja) * | 2007-11-19 | 2009-06-11 | Mitsubishi Gas Chem Co Inc | ２−ヨード−３，４−ジメトキシベンゾニトリルの製造方法 |
| KR102187034B1 (ko) | 2009-01-16 | 2020-12-04 | 엑셀리시스, 인코포레이티드 | 암 치료용 ｎ-（４-｛〔６，７-비스（메틸옥시）퀴놀린-4-일〕옥시｝페닐）-ｎ＇-（４-플루오로페닐）사이클로프로판-1,1-디카르복사미드의 말산염 및 그 결정형 |
| UA108618C2 (uk) | 2009-08-07 | 2015-05-25 | Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку | |
| PE20170331A1 (es) | 2014-03-24 | 2017-04-28 | Guangdong Zhongsheng Pharmaceutical Co Ltd | Derivados quinolina como inhibidores smo |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US875506A (en) * | 1907-03-19 | 1907-12-31 | Berry H Collins | Guiding attachment for penholders. |
| GB1390015A (en) * | 1971-05-07 | 1975-04-09 | Koninklijke Pharma Fab Nv | 4-amino-quinazoline compounds |
| US4026894A (en) * | 1975-10-14 | 1977-05-31 | Abbott Laboratories | Antihypertensive agents |
| US4098788A (en) * | 1977-06-20 | 1978-07-04 | Bristol-Myers Company | Process for preparing quinazolines |
| GR79603B (cs) * | 1982-07-24 | 1984-10-31 | Pfizer | |
| GB8506174D0 (en) | 1985-03-09 | 1985-04-11 | Pfizer Ltd | 4-amino-6 7-dimethoxy-2-piperazin-1-ylquinazoline derivatives |
| IT1270993B (it) | 1994-03-18 | 1997-05-26 | Recordati Chem Pharm | Derivati chinzolilamminici attivi come alfa-antagonisti |
| GB9526546D0 (en) | 1995-12-23 | 1996-02-28 | Pfizer Ltd | Compounds useful in therapy |
| GB9700504D0 (en) | 1997-01-11 | 1997-02-26 | Pfizer Ltd | Pharmaceutical compounds |
| GB9708917D0 (en) * | 1997-05-01 | 1997-06-25 | Pfizer Ltd | Compounds useful in therapy |
| GB9711650D0 (en) | 1997-06-05 | 1997-07-30 | Pfizer Ltd | Compounds useful in therapy |
-
1997
- 1997-01-11 GB GBGB9700504.5A patent/GB9700504D0/en active Pending
- 1997-11-18 TW TW086117203A patent/TW444013B/zh not_active IP Right Cessation
- 1997-12-13 SA SA97180705A patent/SA97180705B1/ar unknown
-
1998
- 1998-01-05 HN HN1998000002A patent/HN1998000002A/es unknown
- 1998-01-05 PE PE1998000006A patent/PE44499A1/es not_active Application Discontinuation
- 1998-01-06 CN CNB011432918A patent/CN1191249C/zh not_active Expired - Fee Related
- 1998-01-06 AT AT98904058T patent/ATE242238T1/de not_active IP Right Cessation
- 1998-01-06 CN CN98801748A patent/CN1093858C/zh not_active Expired - Fee Related
- 1998-01-06 DE DE69815313T patent/DE69815313T2/de not_active Expired - Lifetime
- 1998-01-06 EP EP98904058A patent/EP0968208B1/en not_active Expired - Lifetime
- 1998-01-06 JP JP53056598A patent/JP3357677B2/ja not_active Expired - Lifetime
- 1998-01-06 SK SK907-99A patent/SK284779B6/sk unknown
- 1998-01-06 ES ES98904058T patent/ES2198695T3/es not_active Expired - Lifetime
- 1998-01-06 PT PT98904058T patent/PT968208E/pt unknown
- 1998-01-06 CA CA002277473A patent/CA2277473C/en not_active Expired - Fee Related
- 1998-01-06 AP APAP/P/1998/001175A patent/AP819A/en active
- 1998-01-06 YU YU31699A patent/YU31699A/sh unknown
- 1998-01-06 PA PA19988444301A patent/PA8444301A1/es unknown
- 1998-01-06 PL PL98334678A patent/PL334678A1/xx unknown
- 1998-01-06 SI SI9830477T patent/SI0968208T1/xx unknown
- 1998-01-06 IL IL13076298A patent/IL130762A/xx not_active IP Right Cessation
- 1998-01-06 HU HU0000942A patent/HUP0000942A3/hu unknown
- 1998-01-06 EA EA199900531A patent/EA002851B1/ru not_active IP Right Cessation
- 1998-01-06 ID IDW990660A patent/ID21863A/id unknown
- 1998-01-06 NZ NZ336302A patent/NZ336302A/xx unknown
- 1998-01-06 WO PCT/EP1998/000143 patent/WO1998030560A1/en active IP Right Grant
- 1998-01-06 DK DK98904058T patent/DK0968208T3/da active
- 1998-01-06 AU AU62088/98A patent/AU724990B2/en not_active Ceased
- 1998-01-06 US US09/341,228 patent/US6169093B1/en not_active Expired - Lifetime
- 1998-01-06 TR TR1999/01604T patent/TR199901604T2/xx unknown
- 1998-01-06 CZ CZ19992436A patent/CZ295580B6/cs not_active IP Right Cessation
- 1998-01-06 KR KR1019997006241A patent/KR100347472B1/ko not_active Expired - Fee Related
- 1998-01-06 BR BR9807068-1A patent/BR9807068A/pt not_active Application Discontinuation
- 1998-01-07 MA MA24920A patent/MA26465A1/fr unknown
- 1998-01-07 TN TNTNSN98004A patent/TNSN98004A1/fr unknown
- 1998-01-08 HR HR980010A patent/HRP980010B1/xx not_active IP Right Cessation
- 1998-01-08 AR ARP980100091A patent/AR010396A1/es unknown
- 1998-01-09 MY MYPI98000094A patent/MY119623A/en unknown
- 1998-01-09 ZA ZA98166A patent/ZA98166B/xx unknown
- 1998-06-01 UA UA99073901A patent/UA62945C2/uk unknown
- 1998-06-07 DZ DZ980004A patent/DZ2394A1/xx active
-
1999
- 1999-06-25 IS IS5093A patent/IS2012B/is unknown
- 1999-07-07 BG BG103560A patent/BG63918B1/bg unknown
- 1999-07-08 OA OA9900152A patent/OA11074A/en unknown
- 1999-07-09 NO NO19993396A patent/NO318609B1/no unknown
-
2000
- 2000-06-02 US US09/586,503 patent/US6365599B1/en not_active Expired - Fee Related
-
2001
- 2001-11-13 US US10/007,753 patent/US6521629B2/en not_active Expired - Fee Related
-
2002
- 2002-12-13 US US10/318,902 patent/US6653302B2/en not_active Expired - Fee Related
-
2003
- 2003-09-17 HK HK03106677.4A patent/HK1054389B/zh not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL130762A (en) | Quinoline and quinazoline compounds, pharmaceutical compositions comprising them, process for their preparation and use thereof in the manufacture of medicaments for the treatment of benign prostatic hyperplasia | |
| HUP0301046A3 (en) | Quinazoline derivatives for the treatment of tumours, process for their preparation and pharmaceutical compositions containing them | |
| HUP0204226A3 (en) | Quinazoline derivatives, pharmaceutical compositions containing them, their use and process for the preparation of the compounds | |
| IL149034A (en) | Quinazoline derivatives, processes for their preparation, pharmaceutical compositions containing them and use thereof in the manufacture of medicaments for use in the production of an antiangiogenic and/or vascular permeabiltiy reducing effect | |
| HUP0105133A3 (en) | Quinoline derivatives and quinazoline derivatives, pharmaceutical compositions containing them and their use | |
| EP1045636A4 (en) | PHARMACEUTICAL COMPOSITIONS AND METHOD OF USING THE SAME FOR TREATING FAILURE MYOCARDIAL TISSUES | |
| HUP0204399A3 (en) | Pteridine compounds for the treatment of psoriasis, process for their preparation, pharmaceutical compositions containing them and their use | |
| HUP0004286A3 (en) | Use of quinazoline derivatives for producing pharmaceutical compositions for treating colonic polyps | |
| HUP0001170A3 (en) | Pharmaceutical compositions containing benzimidazole-2-carbamate derivatives as active ingredients for the treatment of viral infections and cancer | |
| HUP0105114A3 (en) | Quinazolinone derivatives, pharmaceutical compositions containing them, their use and process for their preparation | |
| HUP9903732A3 (en) | Use of cgmp elevators for the preparation of pharmaceutical compositions treating benign prostatic hyperplasia | |
| IL147217A0 (en) | New spirooxindole derivatives and pharmaceutical compositions containing the same for treatment of pain | |
| CZ20011652A3 (cs) | Farmaceutický přípravek zahrnující moxifloxacin, způsob výroby a použití tohoto přípravku | |
| EE04965B1 (et) | Imidasoimidasoolid ja triasoolid kui p?letikuvastased hendid, nende kasutamine ravimite valmistamiseks ning farmatseutiline kompositsioon | |
| IL155278A (en) | Compressed Pyridine-4-On and Pyridine-4-On Derivatives | |
| HUP0203238A3 (en) | Drugs for the treatment of malignant tumours, process for their preparation and pharmaceutical compositions containing them | |
| HUP0200309A2 (en) | Arylpiperazinyl-cyclohexyl indole derivatives for the treatment of depression, process for their preparation and pharmaceutical compositions containing them | |
| IL133784A (en) | Dolastatin 15 derivatives, pharmaceutical compositions comprising them and their use in medicaments for treating cancer | |
| GB2343117B (en) | Benzimidazole pharmaceutical composition and process of preparation | |
| EP0799619A3 (en) | Use of alpha1-adrenoreceptor antagonists in the manufacture of a medicament for the prevention and treatment of benign prostatic hyperplasia | |
| PL312079A1 (en) | Derivatives of 3-phenyl isoquinolin-1 (2h)-one, method of obtaining them, therapeutic agent and pharmaceutical composition | |
| HUP0100350A3 (en) | Conjugates useful in the treatment of prostate cancer, pharmaceutical compositions comprising thereof, process for their preparation and their use | |
| HUP0302913A3 (en) | Methods of inducing cancer cell death and tumor regression and preparation of pharmaceutical compositions suitable for treating the same | |
| NO307930B1 (no) | Benzo[f]kinolinoner, farmasøytisk formulering omfattende samme og anvendelse av samme for fremstilling av formulering for behandling | |
| CZ20021489A3 (cs) | N-guanidinoalkylamidy, jejich příprava, pouľití a farmaceutické směsi, které je obsahují |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| MM9K | Patent not in force due to non-payment of renewal fees |